Back سینوفارم AZB Sinopharm Group German Sinopharm Group Basque سینوفارم Persian Sinopharm French Sinopharm Group Armenian Sinopharm Group NB Sinopharm Group Portuguese Sinopharm Group Russian Sinopharm Group Swedish
 logo of Sinopharm Group (same as China National Pharmaceutical Group), with bilingual name on the right | |||||
| Company type | public | ||||
|---|---|---|---|---|---|
| |||||
| ISIN | CNE100000FN7 | ||||
| Industry | Pharmaceutical | ||||
| Founded |
| ||||
| Founder | China National Pharmaceutical Group | ||||
| Headquarters | Sinopharm Plaza, , China | ||||
Area served | China | ||||
Key people |
| ||||
| Revenue |  CN¥227.069 billion (2015) | ||||
| CN¥9.169 billion (2015) | |||||
| CN¥3.761 billion (2015) | |||||
| Total assets | CN¥138.267 billion (2015) | ||||
| Total equity | CN¥30.052 billion (2015) | ||||
| Owner | Sinopharm Industrial Investment (56.79%) | ||||
| Parent | Sinopharm Industrial Investment | ||||
| Subsidiaries | Sinopharm CNMC | ||||
| Footnotes / references in a consolidated basis; equity and profit excluded minority interests; in Hong Kong Financial Reporting Standards[1] | |||||
| Sinopharm Group Co., Ltd. | |||
|---|---|---|---|
| Simplified Chinese | 国药控股股份有限公司 | ||
| Traditional Chinese | 國藥控股股份有限公司 | ||
| Literal meaning | Sinopharm Holding Joint-Stock Limited Company | ||
| |||
| Sinopharm Group | |||
| Simplified Chinese | 国药控股 | ||
| Traditional Chinese | 國藥控股 | ||
| Literal meaning | Sinopharm Holding | ||
| |||
| Second alternative Chinese name | |||
| Simplified Chinese | 国控股份有限公司 | ||
| Traditional Chinese | 國控股份有限公司 | ||
| |||
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Its H shares were listed on the Hong Kong Stock Exchange in 2009,[2] with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list.[3]
- ^ "2015 Annual Report" (PDF). Sinopharm Group. Hong Kong Stock Exchange. 25 April 2016. Retrieved 22 November 2016.
- ^ "China's Sinopharm gets OK for $1 bln HK IPO". Reuters. 2009-07-29. Retrieved 2020-11-14.
- ^ "Sinopharm Group". Forbes. Retrieved 2020-11-14.